Your account is not claimed yet. You can sign up with ORCID to claim your account.

Louis M Aledort (L Aledort, Louis Aledort)

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 4

Top Topics

Clinical Practice

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Icahn School of Medicine at Mount Sinai

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Icahn School of Medicine at Mount Sinai

United States

MD, MACP :: Hematology/Oncology

Publications

Erik Berntorp, Snejana Krassova, Louis M Aledort
In response to WFH guidelines for the management of haemophilia, 3rd edition: Is there a difference between extended-half-life FVIII products or not? Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Louis M Aledort, Shannon L Carpenter, Adam Cuker, Roshni Daniel Kulkarni, Michael Recht, Guy Aaron Young, Cindy Leissinger
Why plasma-derived factor VIII? Haemophilia : the official journal of the World Federation of Hemophilia 25 (3) (2019)
Louis M Aledort
The ongoing imperative for immune tolerance induction in inhibitor management. Haemophilia : the official journal of the World Federation of Hemophilia 25 (2) (2019)
Manuel D Carcao, T Lambert, C Leissinger, C Escuriola-Ettingshausen, E Santagostino, Louis M Aledort, null null
Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis. Haemophilia : the official journal of the World Federation of Hemophilia 24 (6) (2018)